VectorY Therapeutics

Barbara Sanders, Ph.D., Chief Technology Officer

April 13 | 3:15pm | Dark Horse Consulting Ballroom 

Amsterdam, Netherlands


VectorY Therapeutics is a preclinical biotech company that develops vectorized antibody treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Huntington’s and Parkinson’s disease. Our lead program, VTx-001 targeting oxidized phospholipids (OxPC) in ALS, is currently in preclinical development. Our platform consists of engineered AAV vectors, transformative antibodies (VecTabs), antibody/degron fusion proteins (VecTrons), and proprietary manufacturing processes. Our technology enables long-lasting antibody treatment of the CNS after a single administration that potentially provides much needed disease modifying treatments for neurodegenerative diseases with a high unmet medical need.

By using this website you agree to accept our Privacy Policy and Terms & Conditions